Pharmaceutical News

RSS

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Oxygen Biotherapeutics, Inc. today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury.

2 Mar 2011

Study: 700,000 drug-related ED visits cost nearly $1.4 billion in 2007

Over the past decade, drug-related poisonings have been on the rise in the United States. In fact, in many states drug-related poisoning deaths have now surpassed motor vehicle crash fatalities to become the leading cause of injury death. While the fatalities from this epidemic have been well reported, they are only the tip of the iceberg.

2 Mar 2011

Study: Pycnogenol- offers natural solution for patients with metabolic syndrome

The American Heart Association estimates 35 percent of adults in the U.S. suffer from metabolic syndrome, a group of risk factors characterized by obesity and the simultaneous presence of heart disease risk factors with high blood pressure, blood sugar and lipids.

2 Mar 2011

Research: Tanning bed exposure can lead to serious skin problems

Tanning bed exposure can produce more than some tanners may bargain for, especially when they self-diagnose and use the radiation to treat skin eruptions, according to research conducted by the Indiana University School of Medicine Department of Dermatology.

2 Mar 2011

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Apricus Biosciences, Inc. announced today that the European Patent Office will grant a patent for the company's MycoVa product for treating onychomycosis.

2 Mar 2011

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.

1 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

FDA approves roflumilast to treat COPD

The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups or worsening of symptoms from severe chronic obstructive pulmonary disease.

1 Mar 2011

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

New therapeutic strategy improves superior renal function after kidney transplantation

Researchers at Charité - Universitätsmedizin Berlin, together with 16 other transplant centers in Germany and Switzerland successfully tested a new therapeutic strategy that allows for superior renal function after kidney transplantation. The results were published online in the journal "The Lancet".

1 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Anti-AIDS gel shows promise

Dr. Ian McGowan, a professor of medicine at the University of Pittsburgh who is leading a second-phase study of the gel said, “These are early results, but [they] help set the stage for current and future trials of rectal microbicides and the development of a rectal-specific formulation of tenofovir gel.” Researchers have focused on the use of microbicides such as tenofovir, as a preventive treatment to be used in vaginal sex. However, scientists think unprotected anal sex is much more risky.

1 Mar 2011

Medical experts propose six-point framework for safe production and use of Kava plant

Medical and scientific experts propose a global framework for the safe production and use of the medicinal plant Kava, including further clinical testing In Australia.

1 Mar 2011

Decision Resources: 52% of surveyed cardiologists identify furosemide as efficacious acute heart failure therapy

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highest proportion of surveyed cardiologists identify furosemide as the most efficacious agent for the treatment of acute heart failure when compared to other available therapies.

1 Mar 2011

Excella achieves SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that Excella GmbH in Feucht, Germany has met the criteria established under the SafeBridge program for "Potent Compound Safety Certification" and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients ("APIs") and potent drug products.

1 Mar 2011

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.

1 Mar 2011

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Patients in Sweden living with peripheral neuropathic pain are set to gain access to a new treatment option which can provide pain relief for up to three months following a single 30- or 60-minute application. The new treatment patch uses capsaicin - the substance found in chilli peppers which gives them their 'heat' - to change the function of pain sensing nerves in the area of skin affected.

1 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

Novavax announces agreement to license VLP vaccine technology to LGLS

Novavax, Inc. announced today an agreement to license its proprietary, recombinant virus-like-particle vaccine technology to LG Life Sciences, Ltd.

1 Mar 2011

HP announces innovative drug research application for its inkjet technology

HP today announced an innovative drug research application for its inkjet technology that enables pharmaceutical companies to more efficiently develop better drugs through vastly more precise dispensing of dosages.

1 Mar 2011